Physician profile
James B Marx
NPI 1306817986
$2,453.70
in general payments reported to CMS, 2019-2025
28 companies · $47.53 in 2025
The $47.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $674 · 2021: $786 · 2022: $61.14 · 2023: $112 · 2024: $25.20 · 2025: $47.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $508.44 | 2019-2022 | |
| Abbvie INC. | $312.14 | 2020-2025 | |
| Lilly USA, LLC | $285.60 | 2019-2022 | |
| Novo Nordisk INC | $256.92 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.10 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $121.25 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.22 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $75.96 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.59 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $53.16 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $50.34 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $42.35 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.87 | 2019-2021 | |
| Eisai INC. | $37.97 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.12 | 2019 | |
| Allergan, INC. | $28.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.28 | 2019-2020 | |
| Amarin Pharma, INC. | $25.81 | 2020 | |
| Daiichi Sankyo INC. | $22.13 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.00 | 2020 | |
| Antares Pharma, INC. | $16.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.53 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Biodelivery Sciences International, INC. | $12.38 | 2021 | |
| Genentech USA, INC. | $11.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.37 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marx listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.